NA 1

Drug Profile

NA 1

Alternative Names: NA-1; Tat-NR2B9c

Latest Information Update: 01 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arbor Vita Corporation; NoNO
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action PDZ domain inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke

Most Recent Events

  • 27 Feb 2017 NoNO initiates enrolment in the phase III ESCAPE-NA1 trial for Stroke in Canada (NCT02930018)
  • 14 Oct 2016 NoNO Inc. plans a phase III trial for Stroke in Canada (NCT02930018)
  • 28 Aug 2015 NoNO terminates the phase II ENACT-2 trial for Subarachnoid haemorrhage in USA prior to enrolment intiation (NCT02056574)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top